Recurrent Head and Neck Squamous Cell Carcinoma Clinical Trials in Philadelphia, Pennsylvania

4 studies are recruiting for recurrent head and neck squamous cell carcinoma in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

   This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary s…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Jefferson Torresdale Hospital, Philadelphia, Pennsylvania

   Locations

   199 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06589804 on ClinicalTrials.gov

2. Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

   This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head …

   Stage

   Phase 2

   Ages

   18 to 79

   Site

   Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

   Locations

   178 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04671667 on ClinicalTrials.gov

3. A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

   The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cet…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Locations

   112 in total

   Run by

   AVEO Pharmaceuticals, Inc.

   See if you can join NCT06064877 on ClinicalTrials.gov

4. A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

   The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn about the safety of ASP-1929 PIT in combination with pembroliz…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

   Locations

   22 in total

   Run by

   Rakuten Medical, Inc.

   See if you can join NCT06699212 on ClinicalTrials.gov